CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications. The $4.22 (76%) decline...

The European Commission is in the midst of creating Horizon Europe, the successor to Horizon 2020, and this time around it aims to do more to ensure technologies created through the program are advanced by...

As major biopharmas are scaling back Alzheimer’s disease programs following the spate of late-stage amyloid blowups, NIH is making a push for early stage drug discovery in the indication with the formation of two new...

Rare disease patients, advocates and caregivers who spoke at an FDA workshop on Monday highlighted multiple common symptoms across various diseases that could be used to streamline drug development. Attendees also cited the need for...

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...

Harvard physician scientist Michael Fox is using brain imaging to map neurological symptoms to the circuits that drive them, and thinks his connectivity maps can yield opportunities for drug developers. Fox, an associate professor of...

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...

A Stanford University team has developed an AI platform that combines genomic and electronic health record data to help manage the risk of disease and identify new therapeutic targets. The group plans to out-license the...